NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
62332-0565-30 | 62332-0565 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
42292-0053-05 | 42292-0053 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan 31, 2021 | No Longer Used |
59923-0726-30 | 59923-0726 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 1, 2020 | In Use | |
63304-0096-30 | 63304-0096 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | In Use | |
70771-1522-07 | 70771-1522 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
31722-0264-30 | 31722-0264 | ERLOTINIB | ERLOTINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 24, 2024 | In Use | |
55513-0954-01 | 55513-0954 | Panitumumab | Vectibix | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
59651-0530-03 | 59651-0530 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
00409-5255-25 | 00409-5255 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Nov 14, 2022 | In Use | |
64950-0344-16 | 64950-0344 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/5mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Jun 1, 2024 | In Use | |
00703-4502-84 | 00703-4502 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Aug 17, 2015 | Mar 31, 2021 | In Use |
67296-1738-08 | 67296-1738 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Nov 1, 2019 | In Use | |
51662-1367-01 | 51662-1367 | Metoclopramide | Metoclopramide | 10.0 mg/2mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Oct 14, 2019 | In Use | |
70934-0548-30 | 70934-0548 | Metoclopramide | Metoclopramide | 10.0 mg/1 | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Oral | Feb 26, 2020 | In Use | |
23155-0240-41 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan 3, 2014 | In Use | |
55154-0452-05 | 55154-0452 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Dec 9, 2010 | Mar 31, 2013 | No Longer Used |
83634-0779-02 | 83634-0779 | Metoclopramide hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jun 30, 2024 | In Use | |
51662-1288-01 | 51662-1288 | METOCLOPRAMIDE | METOCLOPRAMIDE | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Sep 22, 2018 | In Use | |
00409-3414-01 | 00409-3414 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Feb 2, 2006 | In Use | |
55154-0450-05 | 55154-0450 | Metoclopramide Hydrochloride | Metoclopramide Hydrochloride | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Dec 10, 1993 | In Use | |
51662-1288-03 | 51662-1288 | METOCLOPRAMIDE | METOCLOPRAMIDE | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Oct 1, 2022 | In Use | |
55154-2353-08 | 55154-2353 | METOCLOPRAMIDE | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Sep 22, 2009 | Feb 28, 2019 | In Use |
23155-0240-42 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan 3, 2014 | In Use | |
23155-0240-43 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan 3, 2014 | In Use |
Found 11765 results — Export these results